4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Kymera Therapeutics, Inc. (KYMR) operates in the Biotechnology industry and is headquartered in Watertown, United States with about 253 employees. Its market capitalization is roughly $10 billion. In the fiscal year ended 2025-12-31, KYMR reported $39M in revenue and ($311M) in net income.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
Interactive charts & full statements → Open the KYMR valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $39M | $47M | $79M | $47M |
| Operating Income (EBIT) | ($346M) | ($257M) | ($166M) | ($161M) |
| Net Income | ($311M) | ($224M) | ($147M) | ($155M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $34M | $3M | $3M | $12M | $22M | — |
| Operating Income (EBIT) | ($84M) | ($98M) | ($89M) | ($85M) | ($74M) | — |
| Net Income | ($69M) | ($87M) | ($82M) | ($77M) | ($66M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $1.7B | $978M | $576M | $603M | — |
| Total Liabilities | $163M | $142M | $181M | $113M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KYMR viewer.
About TickerBase · Data methodology & sources